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Key Points 
x SerenoCem GranulesTM are a pre-set glass ionomer cement and are associated with abnormal 
resorption of bone adjacent to the site of implantation when used in mastoid obliteration 
x This was a completely new clinical situation with erosion occurring in asymptomatic patients. 
Advice was sort from the MHRA leading otologists and radiologists. The MHRA advised that 
patients should be recalled, examined and CT scanned to determine the nature of the problem.  
x SerenoCem GranulesTM contain a trace of aluminium but are pre-set, which means that the 
vast majority of aluminium is released in the setting phase and should not constitute a 
neurotoxicity risk 
x Lack of progression on CT findings suggests erosion occurs early on and stabilizes  
x Regulatory standards of the 1990s were perhaps not sufficiently robust and nowadays a more 
exacting clinical trial would be needed 
 
Introduction 
Mastoid obliteration has been performed with various materials including muscle, fat, cartilage, 
musculoperiosteal flaps, chips and pâté1. Biocompatible materials used since the 1960s, have a 
number of potential advantages over autologous tissue. They are sterile, available off the shelf without 
the need for harvest and have a low risk of implanting cholesteatoma.  
SerenoCem GranulesTM (Corinthian Medical Ltd, Nottingham,UK) are a pre-set version of 
SerenoCemTM ionomeric cement, which is a bone-bonding and bioactive material released on the 
market since 1999.  Extensive in-vitro and in-vivo studies have demonstrated that specific Glass 
Ionomer Cement(GIC) compositions have excellent biocompatibility using both bone cells and 
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tissues2,3. Furthermore, when first adopted for use in bone repair, early examples of set cement 
granules showed desirable bony integration when implanted into the rat femur8. This early work led in 
time to their clinical use and they were eventually marketed as ideal material for use in mastoid 
obliteration.  
SerenoCem GranulesTM have been sold in the UK only and employed in approximately 1500 cases. 
The SerenoCemTM cement formulation on which the granular bone graft substitute was based has a CE 
mark for mastoid surgery, with no adverse events reported for this cement.  This paper reports our 
experience with SerenoCem GranulesTM in mastoid obliteration and associated bony erosion. 
 
Methods 
Ethical Considerations 
At the time of each procedure SerenoCem GranulesTM were an established product licensed for use 
therefore no ethical approval was required. 
Patients  
This is a retrospective review conducted as the senior authors became aware of abnormal resorption 
of bone adjacent to SerenoCem GranulesTM. Patients with open cavities were initially selected for 
mastoid obliteration due to chronic otorrhoea. Those with closed cavities were obliterated at a 
combined approach tympanoplasty Stage-2 procedure. Furthermore, no SerenoCemTM granules were 
placed directly on dura. 
Radiological classification  
A classification system for CT findings was devised to quantify the amount of bony erosion across 
three subsites (tegmen, posterior fossa (sigmoid notch and medial to the notch) and the otic 
capsule)(Figure1a,1b). The number of subsites for each patient was then recorded(table1).  
Results 
CA results  
45 (25 males,20 females) cases were performed between 2001-2010, with a mean age of 28.8 
years(range,6-73). Seventeen cases were performed on open mastoid cavities and 28 as part of a 
stage-2 combined approach tympanoplasty.  
 
Median post-operative follow-up for this cohort was 85 months,range(1-192). Four patients developed 
an immediate post-operative infection, in two of these patients the SerenoCem GranulesTM extruded. 
 
Overall, 13 patients underwent revision surgery including two patients with recurrent disease and one 
with residual disease.  
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
IB results 
19 (14 males,5 females) cases were performed between 2001-2015 with a mean age of 43.9 
years,range(21-77). All obliterations were performed on open mastoid cavities in this group. Median 
post-operative follow up was 140.21months,range(14-182). None of the patients had residual or 
recurrent disease and revision surgery was performed for wet mastoid cavities. The average number 
RIVXEVLWHVVKRZLQJERQ\HURVLRQLQ,%¶V results was 0.74(table1). 
 
Two patients within this series underwent obliteration with SerenoCem GranulesTM on one side and 
obliteration with bone pâté alone on the contralateral side. Interestingly, they only displayed bony 
erosion on the side where the SerenoCem GranulesTM were used(figure2). Interval scans on two 
patients suggest bony erosion occurs early on and does not progress. 
 
During revision surgery both surgeons noted that the granules were surrounded by soft tissue with no 
evidence of bony integration. For both obliteration as part of a stage-2 combined approach 
tympanoplasty and obliteration of an open cavity the average number of subsites showing bony 
erosion was 1.38(table1). 
 
Histology  
Histological review of tissue sampling adjacent to the site of SerenoCem GranulesTM revealed local 
inflammation, giant cell reaction and fibrous tissue encapsulation without evidence of bone 
regeneration or osseointegration(figure3).  
 
Discussion 
 Synopsis of key findings 
In 2015, CA operated on a patient with a small recurrent cholesteatoma and removed SerenoCem 
GranulesTM from the mastoid cavity. Extensive bony erosion was noted adjacent to the SerenoCem 
GranulesTM , but unrelated to the cholesteatoma. In particular, the tegmen tympani, tegmen 
mastoideum, posterior external auditory canal wall, and the bone over the posterior fossa, facial canal 
and lateral semicircular canal were widely eroded. Following these observations, patients in whom 
SerenoCem GranulesTM had been used were recalled for review and bony erosions were identified on 
CT imaging.  
 
Comparisons with other studies 
Currently, there is one paper in the literature supporting the use of SerenoCemTM granules for mastoid 
obliteration. The authors reported a post-operative improvement on the Glasgow Benefit Inventory 
score as well as a reduction in aural care visits, however, authors also reported that the granules failed 
to osseointegrate4.  
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Several animal studies have been performed using GIC bone substitutes. To date, there are no animal 
studies where SerenoCem GranulesTM were implanted into the mastoid. A previous commercial 
formulation (the IonogranTM prototype) has been inserted into the mid-shaft of a rat femur in-vivo, 
which at four weeks demonstrated increased osteoid formation compared to hydroxyapatite granules. 
There was no associated chronic inflammatory response at 4 weeks5. Whilst the laboratory rat femur 
is a sterile site, in mastoid obliteration, the granules are inserted into a potentially infected and 
inflamed cavity. This raises the possibility of a biofilm reaction, being the causative factor in the 
development of bony erosion described in this series.  
 
SerenoCemTM Granules differ from other GIC preparations, such as Ionocem  
 (aluminium-calcium-fluorosilicate,Ionocem®IONOS-D8031 Seefeld/Obb,Germany), in that they are 
a dried granular preparation. However, other studies have shown a high risk of extrusion with 
ionomeric cement6.  
 
There have been four cases of subacute aluminium myoclonic encephalopathy following closure of a 
skull base defects with IonocemTM cement. Two of these patients developed refractory status 
epilepticus leading to brain failure and subsequent death. It was suggested that high concentrations of 
aluminium in CSF and plasma led to encephalopathy as a result of aluminium leaching from the 
cement7,8.  
 
SerenoCem GranulesTMcontain a trace of aluminium, which may be of concern in those where the 
granules become adjacent to the dura. GICs in their cement form are generally contraindicated in 
situations where they will come into contact with neural tissue or nerves.  
 
Excessive aluminium ion exposure has been implicated in a number of diseases in particular it exerts 
direct genotoxicity in neural cells9. SerenoCem GranulesTM are pre-set, which means the setting phase 
is already complete at the point of sale and it is also washed out during the manufacturing process. 
Aluminium ions will therefore not leach out in large amounts compared to known cases of aluminium 
toxicity, and over time aluminum release from implanted SerenoCem GranulesTM will effectively 
cease.  
 
The relationship between the aluminium content, ion release, and biocompatibility is undoubtedly 
complex. Brook et al reported no correlation between the aluminum content, ion release and 
biocompatibility2. Furthermore, the dura is also a strong barrier protecting neural tissue. While 
relatively little data is available regarding the long term release of aluminium ions from set glass-
ionomers in general or SerenoCem GranulesTM specifically, this information suggested that after 12 
months the amounts of aluminium that may be released are in the parts per million range where they 
are difficult to detect and would not constitute a risk to human health10. 
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Clinical applicability of the study 
Our detection of bony erosions associated with SerenoCem GranulesTM presents a dilemma for 
asymptomatic patients. All patients included in the study have been informed of the association 
between SerenoCem GranulesTM and potential loss of bone. Advice was sought from the Medicines 
and Healthcare Products Regulatory Agency (MHRA), leading otologists and radiologists. All 
affected patients were subsequently recalled. In liason with the manufacturer, Corinthian Medical Ltd, 
and on review of glass ionomer cement use, we have developed a management strategy for these 
patients. Furthermore, Corinthian Medical Ltd, has voluntarily withdrawn the product from the 
market.  
 
Establishing the low risk of potential concerns such as the leaching out of aluminium from the 
granules and progression of bony erosion has been paramount in quantifying the risk associated with 
SerenoCem GranulesTM. Lack of progression on CT in those with implanted SerenoCem GranulesTM 
suggests erosion occurs early following implantation, and the implant sites appear to stabilise in the 
longer term. 
 
In patients with bony erosion on CT scanning it was felt the benefits of removing the granules was 
outweighed by the risks of surgery, and therefore it was suggested patients should be clinically 
reviewed annually with a repeat CT scan after two years. If at this point there was evidence of 
progressive erosion then the patient would be advised to have the granules removed.  
 
Conclusion 
Currently, those that have purchased SerenoCem GranulesTM have been instructed not to use them and 
they have also been withdrawn from the market. The regulatory environment of the 1990s was not 
sufficiently robust, and with current standards any new bone graft substitute, even one based on an 
otherwise biocompatible material, would be subjected to a more exacting clinical trial before use.  
This is because biocompatibility is specific to a given clinical practice or procedure, rather than an 
intrinsic property of the actual biomaterial. We hypothesize that either a foreign body reaction or a 
biofilm-mediated response may be taking place, and this may have become a chronic adverse event 
due to the action of inflammatory cells and cytokines. 
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 Open/closed 
cavity 
Tegmen 
mastoidium 
Posterior 
fossa 
Otic 
capsule Total 
Radiological classification scores in those with obliteration of a stage 2 
combined approach tympanoplasty and open cavities (CA results) 
1 Stage 2 CAT 1 1 0 2 
2 Stage 2 CAT 1 0 0 1 
3 Stage 2 CAT 0 0 0 0 
4 Stage 2 CAT 1 0 0 1 
5 Stage 2 CAT 1 1 0 2 
6 Stage 2 CAT 1 0 0 1 
7 Stage 2 CAT 1 0 0 1 
8 Stage 2 CAT 0 0 0 0 
9 Stage 2 CAT 1 1 1 3 
10 Stage 2 CAT 1 1 1 3 
11 Stage 2 CAT 1 1 0 2 
12 Stage 2 CAT 1 1 0 2 
13 Stage 2 CAT 1 0 0 1 
14 Stage 2 CAT 1 1 0 2 
15 Stage 2 CAT 0 0 0 0 
16 Stage 2 CAT 1 0 0 1 
17 Open cavity 1 0 0 1 
18 Open cavity 1 1 1 3 
19 Open cavity 1 1 0 2 
20 Open cavity 0 0 0 0 
21 Open cavity 1 1 0 2 
22 Open cavity 0 0 0 0 
23 Open cavity 0 1 0 1 
24 Open cavity 1 1 0 2 
25 Open cavity 1 1 0 2 
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Table 1. Subsites associated with bone resorption on CT scanning. 
 
 
26 Open cavity 1 0 1 2 
27 Open cavity 1 0 0 1 
28 Open cavity 0 0 1 1 
29 Open cavity 1 0 0 1 
30 Open cavity 0 0 0 1 
Radiological classification scores in those with obliteration of only open 
cavities (IB results) 
1 Open Cavity 0 0 0 0 
2 Open Cavity 0 0 0 0 
3 Open Cavity 1 0 0 1 
4 Open Cavity 0 0 0 0 
5 Open Cavity 1 1 0 2 
6 Open Cavity 1 1 1 3 
7 Open Cavity 0 0 0 0 
8 Open Cavity 0 0 0 0 
9 Open Cavity 0 0 0 0 
10 Open Cavity 0 0 0 0 
11 Open Cavity 0 0 0 0 
12 Open Cavity 1 0 0 1 
13 Open Cavity 1 0 0 1 
14 Open Cavity 1 0 0 1 
15 Open Cavity 1 0 1 2 
16 Open Cavity 1 0 0 1 
17 Open Cavity 0 0 0 0 
18 Open Cavity 1 1 0 2 
19 Open Cavity 0 0 0 0 
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